Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06010017 · ClinicalTrials.gov registry record · NA
Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
A NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 136
- Enrollment target
- 2
- Study locations
NCT06010017: Completed NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms, sponsored by Brigham and Women's Hospital.
NCT06010017 is a NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 136 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06010017, a NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT). The name of the intervention used in this research study is STEPP, a peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, tailored to the unique needs of patients undergoing HSCT.
Primary Outcome
The proposed STEPP intervention will be deemed feasible if at least 60% of eligible patients are enrolled in the study, and of those enrolled and randomized to the intervention, at least 60% complete at least 3/5 of the intervention sessions.
Conditions Studied
Interventions
- BEHAVIORAL STEPP Intervention
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2025-03-21 |
| Phase | NA |
What the finished NCT06010017 record still lists
NCT06010017 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Hematopoietic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which STEPP Intervention is the first listed.
NCT06010017 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06010017 about?
NCT06010017 is a clinical study titled "Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation". The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT). The name of the intervention used in this research study is STEPP, a peer support intervention comprised of five learning...
What is the current status of trial NCT06010017?
This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2024-02-20. Estimated completion is 2025-03-21.
What conditions does trial NCT06010017 study?
This clinical trial studies the following conditions: Hematopoietic Malignancy, Hematopoietic Neoplasms.
What interventions are being tested in trial NCT06010017?
The interventions under investigation include: STEPP Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06010017?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06010017 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06010017's enrollment target sits among peer trials
136 722nd of 2000 higher than 1,275 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI